Retinal-conjugated pH-sensitive micelles induce tumor senescence for boosting breast cancer chemotherapy.

[1]  Y. C. Lee-Kim,et al.  Effects of retinoic acid isomers on apoptosis and enzymatic antioxidant system in human breast cancer cells , 2009, Nutrition research and practice.

[2]  Goberdhan P Dimri,et al.  Mechanisms of cellular senescence in human and mouse cells , 2004, Biogerontology.

[3]  Changren Zhou,et al.  Polysaccharides-based nanoparticles as drug delivery systems. , 2008, Advanced drug delivery reviews.

[4]  J. Carey,et al.  Id4 promotes senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate cancer cells. , 2013, Anticancer research.

[5]  C. Rochette-Egly,et al.  The molecular physiology of nuclear retinoic acid receptors. From health to disease. , 2011, Biochimica et biophysica acta.

[6]  Lingrong Liu,et al.  Anti-tumor drug delivery system based on cyclodextrin-containing pH-responsive star polymer: in vitro and in vivo evaluation. , 2014, International journal of pharmaceutics.

[7]  L. Gudas,et al.  Retinoids, retinoic acid receptors, and cancer. , 2011, Annual review of pathology.

[8]  A. Pavlick,et al.  A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer , 2011, Investigational New Drugs.

[9]  Jianping Zhou,et al.  Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system. , 2012, Biomaterials.

[10]  J. Clohessy,et al.  Pro-senescence therapy for cancer treatment , 2011, Nature Reviews Cancer.

[11]  Yue Xiong,et al.  Signaling pathways that control cell proliferation. , 2013, Cold Spring Harbor perspectives in biology.

[12]  P. Adamson,et al.  Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  I. Roninson,et al.  Induction of senescence‐associated growth inhibitors in the tumor‐suppressive function of retinoids , 2003, Journal of cellular biochemistry.

[14]  Mei Han,et al.  HDAC2 phosphorylation-dependent Klf5 deacetylation and RARα acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs , 2011, Cell Research.

[15]  Jin-Zhi Du,et al.  Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. , 2011, Journal of the American Chemical Society.

[16]  Y. Wan,et al.  Retinoid pathway and cancer therapeutics. , 2010, Advanced drug delivery reviews.

[17]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[18]  M. Serrano,et al.  Senescence in tumours: evidence from mice and humans , 2010, Nature Reviews Cancer.

[19]  N. Hay,et al.  Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. , 2008, Cancer cell.

[20]  J. Campisi,et al.  Cellular senescence: when bad things happen to good cells , 2007, Nature Reviews Molecular Cell Biology.

[21]  Jianping Zhou,et al.  Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid , 2014, International journal of nanomedicine.

[22]  Stephen L. Abrams,et al.  Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells , 2011, Oncotarget.

[23]  Eric P. Winer,et al.  Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial , 1997, Cancer Chemotherapy and Pharmacology.

[24]  Joo Song Lim,et al.  All-trans retinoic acid induces cellular senescence via upregulation of p16, p21, and p27. , 2011, Cancer letters.

[25]  Q. Qian,et al.  A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect , 2012, Journal of cellular and molecular medicine.

[26]  S. Friedman,et al.  Retinoids in cancer chemoprevention. , 2004, Current cancer drug targets.

[27]  G. McArthur,et al.  The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma , 2013, Clinical Cancer Research.

[28]  Z. Shao,et al.  Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. , 1994, The Journal of biological chemistry.

[29]  Kinam Park.  Controlled drug delivery systems: past forward and future back. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[30]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. Couvreur,et al.  A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity , 2014, Proceedings of the National Academy of Sciences.

[32]  H. Gronemeyer,et al.  Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. , 2009, Chemistry & biology.

[33]  A. Rishi,et al.  Elevated expression of retinoic acid receptor-α (RARα) in estrogen- receptor-positive breast carcinomas as detected by immunohistochemistry , 1997 .

[34]  Joo Song Lim,et al.  All-trans retinoic acid induces cellular senescence by up-regulating levels of p16 and p21 via promoter hypomethylation. , 2011, Biochemical and biophysical research communications.

[35]  D. Peeper,et al.  The essence of senescence. , 2010, Genes & development.

[36]  Zhiyuan Zhong,et al.  Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. , 2013, Biomaterials.

[37]  A. Iavarone,et al.  Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. H. Park,et al.  Polysaccharide-based nanoparticles: a versatile platform for drug delivery and biomedical imaging. , 2012, Current medicinal chemistry.

[39]  L. Khan,et al.  Amelioration of doxorubicin‑induced cardiotoxicity by resveratrol. , 2014, Molecular medicine reports.

[40]  Hong Yuan,et al.  Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery. , 2010, ACS nano.

[41]  E. Schacht,et al.  Re‐investigation of the 4‐nitrophenyl chloroformate activation of dextran. Evidence for the formation of different types of carbonate moieties , 1985 .

[42]  Jianping Zhou,et al.  Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and Paclitaxel based on hyaluronic acid-based multifunctional nanocarrier. , 2013, Molecular pharmaceutics.

[43]  J. Campisi,et al.  Four faces of cellular senescence , 2011, The Journal of cell biology.

[44]  J. Shay,et al.  Hallmarks of senescence in carcinogenesis and cancer therapy , 2004, Oncogene.

[45]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[46]  J. Gil,et al.  Senescence: a new weapon for cancer therapy. , 2012, Trends in cell biology.

[47]  P. Álvarez,et al.  Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. , 2012, Anti-cancer agents in medicinal chemistry.

[48]  K. Huh,et al.  Heparin-folate-retinoic acid bioconjugates for targeted delivery of hydrophobic photosensitizers. , 2013, Carbohydrate polymers.

[49]  龚萍,et al.  Single-Step Assembly of DOX/ICG Loaded Lipid Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination Therapy , 2013 .

[50]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[51]  Hedi Mattoussi,et al.  The state of nanoparticle-based nanoscience and biotechnology: progress, promises, and challenges. , 2012, ACS nano.

[52]  E. Kandel,et al.  A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. , 1999, Cancer research.

[53]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[54]  Ping Li,et al.  Autophagy mediates avian influenza H5N1 pseudotyped particle-induced lung inflammation through NF-κB and p38 MAPK signaling pathways. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[55]  G. Saretzki,et al.  Cellular senescence in the development and treatment of cancer. , 2010, Current pharmaceutical design.

[56]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[57]  S. Cole,et al.  Rapid chemosensitivity testing of human lung tumor cells using the MTT assay , 2004, Cancer Chemotherapy and Pharmacology.

[58]  Xuesi Chen,et al.  Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. , 2014, Biomaterials.

[59]  R. Rosenfeld,et al.  Deciphering the fluorescence signature of daunomycin and doxorubicin. , 1998, Biophysical chemistry.

[60]  S. Sukumar,et al.  Molecular Pathways: Current Role and Future Directions of the Retinoic Acid Pathway in Cancer Prevention and Treatment , 2013, Clinical Cancer Research.

[61]  A. Rishi,et al.  Elevated expression of retinoic acid receptor-alpha (RAR alpha) in estrogen-receptor-positive breast carcinomas as detected by immunohistochemistry. , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.